Sat.Apr 13, 2024 - Fri.Apr 19, 2024

Remove biosimilars-diabetes
article thumbnail

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Express Pharma

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.

Diabetes 105
article thumbnail

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).